WILL BIOGEN AND TEVA CHALLENGE BERLEX IN MS

被引：0

|

作者：

ALPER, J

机构：

来源：

BIO-TECHNOLOGY | 1994年 / 12卷 / 13期

关键词：

D O I：

暂无

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

引用

收藏

页码：1317 / 1318

页数：2

相关论文

共 50 条

[1] Biogen, Berlex settle litigation over interferon patent
不详
BIOTECHNOLOGY LAW REPORT, 2002, 21 (03) : 265 - 265
[2] Berlex continues legal challenge to FDA over MS drug
Glaser, V
NATURE BIOTECHNOLOGY, 1996, 14 (07) : 811 - 812
[3] Biogen says Berlex patent suit is without merit and will not affect market launch of Avonex
不详
DRUG NEWS & PERSPECTIVES, 1996, 9 (06) : 364 - 364
[4] CHALLENGE FROM BIOGEN
FEINSTEIN, P
BIO-TECHNOLOGY, 1985, 3 (10): : 849 - 849
[5] Natalizumab treatment satisfaction in the TONiC-MS study: preliminary resultssupport from NIHR, MNDA, Walton Neuroscience Charity, Biogen, Novartis, Roche, Teva
Mills, R.
James, B.
Vonsy, J.
Langdon, D.
Ando, H.
Young, C.
MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 360 - 360
[6] Biogen and Elan pull MS drug
Marx, V
CHEMICAL & ENGINEERING NEWS, 2005, 83 (10) : 8 - 8
[7] UCB, Biogen form MS pact
不详
CHEMICAL & ENGINEERING NEWS, 2006, 84 (41) : 21 - 21
[8] Biogen boosts MS drug portfolio
Cross, Ryan
CHEMICAL & ENGINEERING NEWS, 2017, 95 (48) : 15 - 15
[9] Biogen, Inc. v. Berlex Laboratories Inc and Schering AG (01-1058,-1059)
不详
BIOTECHNOLOGY LAW REPORT, 2003, 22 (03) : 352 - 361
[10] Teva's MS drug edges to the market
Brower, V
NATURE BIOTECHNOLOGY, 1996, 14 (11) : 1536 - 1536

← 1 2 3 4 5 →